Inhibitor Therapeutics, Inc.
INTI
$0.09
$0.0117.03%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.24% | -36.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.07% | -47.11% | |||
| Operating Income | 11.07% | 47.11% | |||
| Income Before Tax | 10.56% | 47.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.56% | 47.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.56% | 47.01% | |||
| EBIT | 11.07% | 47.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 12.50% | 46.67% | |||
| Normalized Basic EPS | 12.00% | 46.81% | |||
| EPS Diluted | 12.50% | 46.67% | |||
| Normalized Diluted EPS | 12.00% | 46.81% | |||
| Average Basic Shares Outstanding | 0.43% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||